5. (Amended) An immunotherapeutic agent of claim 1, wherein the cell lines derived from tumor tissue and are selected from the group consisting of NIH1519-CPTX, NIH1532-CP2TX, NIH1535-CP1TX, NIH1542-CP3TX, CA-HPV-10, LnCap, DU145 and PC3.

B2

9. (Amended) An immunotherapeutic agent of claim 1, wherein the tumor cell lines have been irradiated at 50 to 300 Gy.

10. (Amended) An immunotherapeutic agent of claim 1, wherein the tumor cell lines have been irradiated at 100 to 150 Gy.

11. (Amended) An allogeneic immunogenic composition comprising an immunotherapeutic agent of claim 1 combined with a vaccine adjuvant selected from the group consisting of BCG, *M. Vaccae*, Tetanus toxoid, Diphtheria toxoid, *Bordetella Pertussis*, interleukin 2, interleukin 12, interleukin 4, interleukin 7, Complete Freund's Adjuvant, Incomplete Freund's Adjuvant, and non-specific adjuvants.

12. (Amended) An immunogenic composition comprising an immunotherapeutic agent of claim 1 combined with a vaccine adjuvant, wherein the adjuvant is a mycobacterial preparation.

13. (Amended) An immunotherapeutic agent of claim 1, wherein the cells are formulated with a cryoprotectant solution comprising at least one selected from the group consisting of 10-30% v/v aqueous glycerol solution, 5-20% v/v dimethyl sulphoxide and 5-20% w/v human serum albumin.

14. (Amended) An immunotherapeutic agent of claim 1, wherein the cells are formulated with a cryoprotectant solution comprising 5-20% v/v dimethyl sulphoxide and 5-20% w/v human serum albumin.

15. (Amended) An immunotherapeutic agent of claim 1, wherein said agent induces an immune response in patients characterized by activation of immune T-cells.

16. (Amended) An immunotherapeutic agent of claim 1, wherein said agent induces an immune response in patients characterized by induction of antibody production.

17. (Amended) An immunotherapeutic agent of claim 1, wherein said agent induces a decrease in the rate of rise or a decline in the level of serum PSA in prostate cancer patients.

18. (Amended) An immunotherapeutic agent according to claim 1, wherein said agent is administered intradermally.

19. (Amended) An immunotherapeutic agent according to claim 1, wherein said agent is administered intra-prostatically.

20. (Amended) An allogeneic immunotherapeutic vaccine composition for the treatment of prostate cancer, wherein said composition comprises an agent according to claim 1

and a physiologically acceptable agent selected from the group consisting of an excipient, an adjuvant, and a carrier.

21. (Amended) An allogeneic method of prophylaxis or treatment of prostate cancer by administering to a patient an effective amount of an agent according to claim 1.

22. (Amended) An allogeneic method of using an agent according to claim 1 in the manufacturing of a medicament for the allogeneic treatment of human prostate cancer.

Remarks

By the foregoing, claims 1-22 are pending. An Office Action on the merits is now awaited. Should there be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

September 7, 2001
Date

John P. Isacson
Attorney for Applicant
Reg. No.: 33,715

Heller, Ehrman, White & McAuliffe LLP
1666 K Street, N.W.
Suite 300
Washington, D.C. 20006
Direct: (202) 912-2777
Tel. (202) 912-2000
Fax (202) 912-2020